Johnson & Johnson (JNJ) reports a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.
You are here: Home / J&J’s 2025 drug sales forecast should not be tripping up investors. There’s so much else like
Market News and Views
Johnson & Johnson (JNJ) reports a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.